Next Article in Journal
Using iPSC Models to Understand the Role of Estrogen in Neuron–Glia Interactions in Schizophrenia and Bipolar Disorder
Next Article in Special Issue
Role of Telomeres Shortening in Atherogenesis: An Overview
Previous Article in Journal
COVID-19: Characteristics and Therapeutics
Previous Article in Special Issue
The Impact of HIV- and ART-Induced Mitochondrial Dysfunction in Cellular Senescence and Aging

The Jekyll and Hyde of Cellular Senescence in Cancer

Izmir Biomedicine and Genome Center, Izmir 35340, Turkey
Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35340, Turkey
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2021, 10(2), 208;
Received: 23 December 2020 / Revised: 15 January 2021 / Accepted: 17 January 2021 / Published: 21 January 2021
Cellular senescence is a state of stable cell cycle arrest that can be triggered in response to various insults and is characterized by distinct morphological hallmarks, gene expression profiles, and the senescence-associated secretory phenotype (SASP). Importantly, cellular senescence is a key component of normal physiology with tumor suppressive functions. In the last few decades, novel cancer treatment strategies exploiting pro-senescence therapies have attracted considerable interest. Recent insight, however, suggests that therapy-induced senescence (TIS) elicits cell-autonomous and non-cell-autonomous implications that potentially entail detrimental consequences, reflecting the Jekyll and Hyde nature of cancer cell senescence. In essence, the undesirable manifestations that generally culminate in inflammation, cancer stemness, senescence reversal, therapy resistance, and disease recurrence are dictated by the persistent accumulation of senescent cells and the SASP. Thus, mitigating these pro-tumorigenic effects by eliminating these cells or inhibiting their SASP production holds great promise for developing innovative therapeutic strategies. In this review, we describe the fundamental aspects and dynamics of cancer cell senescence and summarize the comprehensive research on the adverse outcomes of TIS. Furthermore, we underline the rationale and motivation of emerging senotherapeutic modalities surrounding the removal of senescent cells and the SASP to help maximize the overall efficacy of cancer therapies. View Full-Text
Keywords: cancer; cellular senescence; SASP; therapy-induced senescence; senostatic; senolytic cancer; cellular senescence; SASP; therapy-induced senescence; senostatic; senolytic
Show Figures

Figure 1

MDPI and ACS Style

Demirci, D.; Dayanc, B.; Mazi, F.A.; Senturk, S. The Jekyll and Hyde of Cellular Senescence in Cancer. Cells 2021, 10, 208.

AMA Style

Demirci D, Dayanc B, Mazi FA, Senturk S. The Jekyll and Hyde of Cellular Senescence in Cancer. Cells. 2021; 10(2):208.

Chicago/Turabian Style

Demirci, Dilara, Bengisu Dayanc, Fatma Aybuke Mazi, and Serif Senturk. 2021. "The Jekyll and Hyde of Cellular Senescence in Cancer" Cells 10, no. 2: 208.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop